Gregory Balani

Gregory Balani, PharmD, currently serves as a Senior Associate at Avego since October 2024. Prior to this role, Gregory held positions including VC Consultant/IIR at Ally Bridge Group for a brief period in August 2024, and Senior Director, Head of Business Development at Escient Pharmaceuticals from August 2022 until its acquisition by Incyte in May 2024 for $750 million plus cash. Gregory's earlier experience includes serving as Director of Business Development at Zogenix, Inc., where the company was acquired by UCB for $1.9 billion in March 2022. Additional roles include Sr. Manager of Business Development & Licensing at Bayer, Manager of Global Mergers, Acquisitions and Licensing, and Associate in US Business Development & Licensing in the pharmaceutical sector. Gregory's academic background includes a Doctor of Pharmacy from the University of California, San Francisco, and a Bachelor of Science in Finance/Economics from DePaul University.